• Cediranib (AZD2171) In Vitro Assay Guide

  2026-09-02

  Cediranib (AZD2171) enables researchers to connect VEGFR pathway suppression with angiogenesis, proliferation, and cell-death measurements. This practical guide shows how to build more informative dose-response workflows and troubleshoot discordant pathway and viability results.

• Triiodothyronine (T3): From Signaling to Translation

  2026-09-02

  A translational framework for using Triiodothyronine to interrogate receptor-driven metabolism while learning from spatially concentrated base editing in oligodendrocytes. The article connects assay design, reagent rigor, and disease-model strategy without overstating cross-domain evidence.

• Drug-Sensitized Yeast for mTOR Inhibitor Discovery

  2026-09-01

  The 2025 GeroScience study developed a genetically drug-sensitized Saccharomyces cerevisiae platform that detects TOR inhibitors at substantially lower concentrations than conventional yeast backgrounds. Its results validate a rapid screening strategy, identify aminophylline as a TOR1-dependent growth inhibitor, and show that Nebivolol hydrochloride produced no detectable TOR-inhibitory phenotype under the tested conditions.

• hiPSC Intestinal Organoids for Pharmacokinetics

  2026-09-01

  Saito and colleagues developed a direct three-dimensional culture strategy for generating human induced pluripotent stem cell-derived intestinal organoids with sustained expansion, differentiation potential, and cryopreservation capacity. The resulting organoid-derived epithelial cells displayed enterocyte-associated drug-metabolizing enzyme and transporter activities, supporting their use as a human-relevant platform for pharmacokinetic research.

• BMN 673 (Talazoparib) in PARP Research

  2026-08-31

  BMN 673 (Talazoparib) combines exceptionally potent PARP1/2 inhibition with strong PARP-DNA complex trapping, making it useful for modeling functional homologous recombination defects. This guide translates spliceosome-based findings in hepatocellular carcinoma into practical assay workflows, comparison strategies, and troubleshooting decisions.

• hiPSC Intestinal Organoids for Pharmacokinetic Studies

  2026-08-31

  Saito and colleagues established a direct three-dimensional culture strategy for generating human induced pluripotent stem cell-derived intestinal organoids with long-term expansion, cryopreservation, and differentiation capacity. The resulting epithelial cells display CYP3A-mediated metabolism and P-glycoprotein efflux, providing a more human-relevant platform for oral drug pharmacokinetic research than conventional transformed cell models.

• Standardized Whole-Blood Stimulation and Immunometabolism

  2026-08-30

  Zhao and colleagues present a standardized whole-blood stimulation protocol for examining how metabolic interventions shape cytokine responses to innate immune stimuli. Its main contribution is a practical framework that preserves blood-based cellular interactions while enabling reproducible comparison of anabolic and catabolic pathway modulation across samples.

• Engineered Esophagus Achieves Functional Integration

  2026-08-29

  The reference study combines an autologous, cell-seeded decellularized porcine scaffold with bioreactor conditioning, temporary intraluminal support, and a vascularizing pleural wrap. In a growing minipig model, this integrated strategy produced progressive neuromuscular and vascular regeneration, oral-feeding capacity, and secondary peristalsis, while also revealing important translational limitations.

• Morin Workflow for Podocyte Energy Studies

  2026-08-28

  Morin combines pathway-focused bioactivity with fluorescent metal-ion sensing, making it useful for connecting mitochondrial dysfunction to biochemical assay development. This practical guide covers formulation, podocyte energy workflows, aluminum-ion detection, validation controls, and troubleshooting.

• Mechanical Stress-Induced Autophagy and Cytoskeleton

  2026-08-28

  The reference study shows that compressive mechanical stress-induced autophagy depends primarily on cytoskeletal microfilaments, while microtubules make a supporting contribution. Its combination of cytoskeletal perturbation, fluorescence imaging, and western blotting provides a practical framework for studying force-to-autophagy signaling without assuming that all cytoskeletal components have equivalent functions.

• Epacadostat (INCB024360) Assay Workflow

  2026-08-27

  Build a staged IDO1 workflow that connects biochemical potency with whole-blood cytokine profiling, T-cell function, and checkpoint-combination studies. Epacadostat helps distinguish IDO1-driven immune suppression from broader metabolic effects, making it useful for mechanistic immuno-oncology research.

• MRSA Extracellular Vesicles Drive OSCC via IL-8

  2026-08-27

  A 2026 study reports that extracellular vesicles from methicillin-resistant Staphylococcus aureus, unlike vesicles from methicillin-susceptible strains, enhance oral squamous cell carcinoma growth through an ERK/c-Jun–IL-8–CXCR1 signaling axis. Its combined cellular, cargo, pathway-inhibition, and mouse-model experiments position antibiotic-resistant bacteria as active modulators of tumor biology rather than solely as infectious threats.

• Separating Growth Arrest from Cell Death in Cancer

  2026-08-26

  Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its framework separates proliferative arrest from cell killing, improving time-course design, response interpretation, and the translation of in vitro findings into cancer research workflows.

• DiscoveryProbe Protease Inhibitor Library Guide

  2026-08-26

  The DiscoveryProbe Protease Inhibitor Library is a pre-dissolved resource for protease inhibition in biochemical and cell-based screening. Its value combines broad inhibitor coverage with a workflow that separates phenotypic activity from target attribution.

• Inhaled RNA Rebuilds the Lung Cancer TME

  2026-08-25

  The reference study develops an inhalable lipid nanoparticle that co-delivers anti-DDR1 scFv mRNA and PD-L1 siRNA to address both collagen-mediated immune exclusion and checkpoint-mediated immunosuppression in lung tumors. In orthotopic and metastatic mouse models, this combined strategy remodeled collagen architecture, reduced tumor stiffness, promoted tumor regression, and extended survival, providing a mechanistic framework for local RNA immunotherapy.

8414 records 1/561 page Next 12345 下5页 Last page